Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048944 | 0.87 | KDM4E (0.63) | KMT2AKDM4EALDH1A1MEN1HTT | |
| SCHEMBL6251861 | 0.86 | KDM4E (0.65) | KMT2AKDM4EALDH1A1MEN1PRMT5 | |
| SCHEMBL6257973 | 0.85 | KMT2A (0.67) | KMT2AKDM4EALDH1A1MEN1PRMT5 | |
| SCHEMBL6254168 | 0.84 | KDM4E (0.57) | KMT2AKDM4EALDH1A1MEN1PRMT5 | |
| SCHEMBL6252359 | 0.84 | KDM4E (0.57) | KMT2AKDM4EALDH1A1PRMT5HRH3 | |
| SCHEMBL9080633 | 0.84 | KDM4E (0.68) | KMT2AKDM4EALDH1A1HTTPRMT5 | |
| SCHEMBL6252377 | 0.83 | KMT2A (0.68) | KMT2AKDM4EALDH1A1MEN1PRMT5 | |
| SCHEMBL6258132 | 0.83 | KMT2A (0.62) | KMT2AKDM4EALDH1A1MEN1HTT | |
| SCHEMBL6252685 | 0.81 | KDM4E (0.65) | KMT2AKDM4EALDH1A1MEN1HTT | |
| SCHEMBL2704412 | 0.81 | KDM4E (0.65) | KMT2AKDM4EALDH1A1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392643-B1 | TRISUBSTITUTED-N- (1S)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENYL] BENZAMIDES WHICH INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBOTT LAB (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6831193-B2 | Treating pain, urinary incontinence and bladder overactivity; P2X receptors are cation-permeable ion channels | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | ABBVIE INC. | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | KMT2A 3291/4885KDM4E 3321/4885ALDH1A1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.